CD137
抗体
癌症研究
癌症免疫疗法
免疫疗法
化学
T细胞
免疫系统
免疫学
受体
生物
生物化学
作者
Wenqing Li,Xinfu Zhang,Chengxiang Zhang,Jinyue Yan,Xucheng Hou,Shi Du,Chunxi Zeng,Weiyu Zhao,Binbin Deng,David W. McComb,Yuebao Zhang,Diana D. Kang,Junan Li,William E. Carson,Yizhou Dong
标识
DOI:10.1038/s41467-021-27434-x
摘要
Abstract Antibodies targeting costimulatory receptors of T cells have been developed for the activation of T cell immunity in cancer immunotherapy. However, costimulatory molecule expression is often lacking in tumor-infiltrating immune cells, which can impede antibody-mediated immunotherapy. Here, we hypothesize that delivery of costimulatory receptor mRNA to tumor-infiltrating T cells will enhance the antitumor effects of antibodies. We first design a library of biomimetic nanoparticles and find that phospholipid nanoparticles (PL1) effectively deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Then, we demonstrate that the combination of PL1-OX40 mRNA and anti-OX40 antibody exhibits significantly improved antitumor activity compared to anti-OX40 antibody alone in multiple tumor models. This treatment regimen results in a 60% complete response rate in the A20 tumor model, with these mice being resistant to rechallenge by A20 tumor cells. Additionally, the combination of PL1-OX40 mRNA and anti-OX40 antibody significantly boosts the antitumor immune response to anti-PD-1 + anti-CTLA-4 antibodies in the B16F10 tumor model. This study supports the concept of delivering mRNA encoding costimulatory receptors in combination with the corresponding agonistic antibody as a strategy to enhance cancer immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI